Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Arkansas to Ask Court to Reconsider Risperdal Fine

April 4, 2014 1:13 pm | by Andrew DeMillo | News | Comments

Arkansas Attorney General Dustin McDaniel said he plans to ask the state Supreme Court to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson & Johnson over the marketing of the antipsychotic drug Risperdal. Read more...

TOPICS:

Obama Signs $126M Cancer Research Bill

April 4, 2014 1:00 pm | by Nedra Pickler | News | Comments

A 10-year-old Leesburg, Va., girl who died of brain cancer is leaving a legacy for other sick children in a new bipartisan law signed by President Barack Obama. Read more...             

TOPICS:

EU Study Reveals New Causes of Mouth, Throat Cancer

April 4, 2014 11:04 am | News | Comments

Poor oral health and failure to have regular dental checks could increase the risk of mouth and throat cancer, according to a pan-European study. Read more...                           

TOPICS:
Advertisement

Merck, Ferring, WHO to Advance Temperature-Stable Bleeding Drug

April 4, 2014 10:53 am | News | Comments

Merck, Ferring Pharmaceuticals and the WHO are collaborating to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding in women after childbirth, that is designed to be stable at room temperature, even in hot and tropical climates. Read more...

TOPICS:

Nanoparticles Cause Cancer Cells to Self-Destruct

April 4, 2014 10:42 am | Videos | Comments

Using magnetically controlled nanoparticles to force tumor cells to "self-destruct: sounds like science fiction, but could be a future part of cancer treatment, according to new research. Read more...               

TOPICS:

Halozyme Halts Pancreatic Cancer Trial

April 4, 2014 10:36 am | News | Comments

Halozyme Therapeutics announced that as a result of a recommendation from an independent Data Monitoring Committee, the company is temporarily halting patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial in patients with pancreatic cancer. Read more...

TOPICS:

FDA Approves Easy-to-Use Heroin Overdose Antidote

April 4, 2014 10:24 am | by Lauran Neergaard and Mary Clare Jalonick | News | Comments

The FDA approved an easy-to-use device that automatically injects the right dose of an overdose antidote named naloxone before an ambulance arrives, enabling friends and family to take the first step to save a loved one from an overdose before an ambulance arrives. Read more...

TOPICS:

New Drug Prevents Tumor Growth by Inhibiting Key Enzyme

April 4, 2014 10:19 am | Videos | Comments

A ground-breaking has shown that fast-growing cancer cells are sensitive towards imbalances in the metabolism of nucleotides, the building blocks of DNA. This vulnerability can be exploited for a radically novel antitumor therapeutic approach. Read more...

TOPICS:
Advertisement

Physiologically Relevant Cell Culture Handbook

April 3, 2014 5:00 pm | Product Releases | Comments

AMS Biotechnology (AMSBIO) has produced an extensive 48-page handbook for research scientists looking to culture cells in more physiologically relevant environments.

Astellas, Medivation Submit Amended MAA for New Xtandi Use

April 3, 2014 1:22 pm | News | Comments

Astellas Pharma and Medivation announced the submission of a variation to amend the European Marketing Authorization Application for Xtandi (enzalutamide) capsules for a new indication in the treatment of adult men with metastatic castration-resistant prostate cancer. Read more...

TOPICS:

Study Helps Unravel the Tangled Origin of ALS

April 3, 2014 1:14 pm | News | Comments

By studying nerve cells that originated in patients with a severe neurological disease, a University of Wisconsin-Madison researcher has pinpointed an error in protein formation that could be the root of amyotrophic lateral sclerosis. Read more...

TOPICS:

Glenmark's Chronic Inflammatory Disease Drug Enters Human Trials

April 3, 2014 1:00 pm | News | Comments

Glenmark Pharmaceuticals announced that its Novel Chemical Entity (NCE) GRC 27864, a potent, selective, and orally bioavailable inhibitor of Microsomal Prostaglandin E synthase-1 (mPGES-1), is entering Phase 1human trials. Read more...   

TOPICS:

FDA Accepts Omeros IND App for TMA Treatment

April 3, 2014 12:45 pm | News | Comments

Omeros Corp. announced that its Investigational New Drug (IND) Application to evaluate OMS721 for the inhibition of complement mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration (FDA). Read more...

TOPICS:

BioDelivery Sciences Opens Phase 3 Trial of Diabetic Neuropathy Gel

April 3, 2014 12:37 pm | News | Comments

BioDelivery Sciences International Inc. announced the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. Read more...       

TOPICS:

Fertility Drugs Do Not Increase Breast Cancer Risk

April 3, 2014 12:26 pm | News | Comments

Women who took clomiphene citrate or gonadotropins as a part of fertility treatment did not experience an increased risk for breast cancer over 30 years of follow-up, compared with women who were not treated with these medications, according to a study. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading